In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME)

Dmitry Pankov, Ludvig Sjöström, Teja Kalidindi, Sang Gyu Lee, Kjell Sjöström, Rui Gardner, Michael R. McDevitt, Richard O'Reilly, Daniel L.J. Thorek, Steven M. Larson, Darren Veach, David Ulmert

Research output: Contribution to journalArticle

Abstract

Preferentially Expressed Antigen in Melanoma (PRAME) is a cancer/testis antigen that is overexpressed in a broad range of malignancies, while absent in most healthy human tissues, making it an attractive diagnostic cancer biomarker and therapeutic target. Although commonly viewed as an intracellular protein, we have demonstrated that PRAME has a membrane bound form with an external epitope targetable with conventional antibodies. We generated a polyclonal antibody (Membrane associated PRAME Antibody 1, MPA1) against an extracellular peptide sequence of PRAME. Binding of MPA1 to recombinant PRAME was evaluated by Enzyme-Linked Immunosorbent Assay (ELISA). Flow cytometry and confocal immunofluorescence microscopy of MPA1 was performed on multiple tumor cell lines. Reverse Transcription Polymerase Chain Reaction (RTPCR) for PRAME was conducted to compare protein and transcriptional expression levels. We demonstrated a robust proof-of-concept for PRAME targeting in vivo by radiolabeling MPA1 with zirconium-89 (89Zr-DFO-MPA1) and demonstrating high specific uptake in PRAME expressing tumors. To our knowledge, this is the first time a cancer testis antigen has been targeted using conventional antibody technologies. Thus, PRAME can be exploited for multiple clinical applications, including targeted therapy, diagnostic imaging and treatment guidance in a widerange of malignancies, with minimal off-target toxicity.

Original languageEnglish (US)
Pages (from-to)65917-65931
Number of pages15
JournalOncotarget
Volume8
Issue number39
DOIs
StatePublished - 2017

Keywords

  • Cancer
  • Immuno-targeting
  • Noninvasive imaging
  • PRAME
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME)'. Together they form a unique fingerprint.

  • Cite this

    Pankov, D., Sjöström, L., Kalidindi, T., Lee, S. G., Sjöström, K., Gardner, R., McDevitt, M. R., O'Reilly, R., Thorek, D. L. J., Larson, S. M., Veach, D., & Ulmert, D. (2017). In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME). Oncotarget, 8(39), 65917-65931. https://doi.org/10.18632/oncotarget.19579